NCT06267781 RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
| NCT ID | NCT06267781 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Raffaele |
| Condition | Multiple Sclerosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2022-09-02 |
| Primary Completion | 2027-09-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2022-09-02 with a primary completion date of 2027-09-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years; * Signed written informed consent; * A diagnosis of RRMS according to the 2017 Revisions of the McDonald Criteria; * High clinical and magnetic resonance imaging (MRI) inflammatory disease activity (at least 2 clinical relapses, or one clinical relapse with gadolinium (Gd)- enhancing or new T2 MRI lesions at a separate time point, in the previous 12 months) * Patients referred for pharmacological treatment with aHSCT, alemtuzumab or ocrelizumab /ofatumumab, according to clinical practice following the Italian pharmacological regulatory agency (AIFA) criteria and guidelines and recommendations from the European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE); Exclusion Criteria: * Diagnosis of PPMS or SPMS according to the 2017 McDonald criteria * Known intolerances/allergies to the active substance or the excipients contained in the DMT and/or contraindications according to product information
Contact & Investigator
Massimo Filippi
PRINCIPAL INVESTIGATOR
IRCCS San Raffaele
Frequently Asked Questions
Who can join the NCT06267781 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06267781 currently recruiting?
Yes, NCT06267781 is actively recruiting participants. Contact the research team at genchi.angela@hst.it for enrollment information.
Where is the NCT06267781 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06267781 clinical trial?
NCT06267781 is sponsored by IRCCS San Raffaele. The principal investigator is Massimo Filippi at IRCCS San Raffaele. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.